GeneMind Biosciences said China’s NMPA registered its SURFSeq 5000 Dx high-throughput sequencer as a Category III medical device. With registration, the company can deploy the diagnostic version of its platform across the Chinese clinical market for both DNA and RNA sequencing. The company positioned the technology for applications including oncology, inherited disease, reproductive health, and infectious diseases, while noting that the platform is not approved for clinical whole-genome sequencing. GeneMind also referenced prior NMPA approvals for its lower- and mid-throughput sequencers. The move reflects how Chinese sequencing vendors are packaging instruments into regulated, disease-specific diagnostic pathways rather than offering a one-size-fits-all platform.